Results 131 to 140 of about 755,616 (163)
S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
HemaSphere, 2023 Yan Shi, Hu Zhou, Ruibin Huang, Fang Wang, Heng Mei, Lie Lin, Jingming Guo, Xin Zhou, Zhenyu LI, Yaorong Liu, Sichen LI, Wei Zhou, Ming Hou +12 moredoaj +1 more sourcePB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
HemaSphere, 2023 Kim Linton, Francesco Forconi, David Lewis, John Riches, Dima El-Sharkawi, Mary Gleeson, Sarah G Injac, Srinand Nandakumar, May Tan, Ganesh Cherala, Graham P Collins +10 moredoaj +1 more sourceBruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
JAAD Case ReportsShannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD +4 moredoaj +1 more source